整合基于venetoclax的针对性和/或免疫疗法治疗慢性淋巴细胞白血病
David Kegyes1, Ximena Muresan2, Anamaria Bancos3
1Department of Personalized Medicine and Rare Diseases, Medfuture Institute for Biomedical Research, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Critical reviews in oncology/hematology
|March 13, 2026
概括
威尼托克拉克斯 (VEN) 组合为慢性淋巴细胞白血病 (CLL) 提供有效的无化疗治疗,实现深度缓解和长期无进展生存. 基于VEN的疗法对新诊断的和复发/耐药的CLL患者都有希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 作为BCL-2抑制剂的Venetoclax (VEN) 是现代慢性淋巴细胞白血病 (CLL) 治疗的组成部分.
- 基于VEN的组合提供了无化疗的选择,以获得深度,持久的缓解.
研究的目的:
- 审查基于VEN的向和免疫疗法组合,用于新诊断的和复发/耐药的CLL.
- 总结临床试验并讨论VEN治疗中的新兴策略.
主要方法:
- 关键临床试验的叙述性综述.
- 对VEN与抗CD20抗体,BTK抑制剂,双特异性抗体和CAR T细胞组合的评估.
主要成果:
- VEN组合实现了高响应率,持久的无进展生存率和不可检测的最小残留疾病 (MRD).
- 固定的持续时间VEN-obinutuzumab/rituximab超过化疗免疫疗法;与BTK抑制剂一起的VEN增强了反应深度并降低了耐药性.
- 以MRD为指导的策略显示出潜力,但其优越性与固定的持续时间方法相比未被证明.
结论:
- 基于VEN的组合对CLL非常有效,提供固定的持续时间,无化疗治疗,具有深度反应.
- 进一步的研究比较治疗方案和整合MRD引导的决策对于优化CLL治疗至关重要.
相关概念视频
Treatment Resistent Cancers
1.5K
1.5K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine
1.7K
1.7K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
